Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2020-05-14 08:00:00
Oslo, 14 May 2020: Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2020 results today. A presentation by the company's management team will take place today on a webcast at 09:00 CET. The new CEO, Carlos de Sousa, who will join Ultimovacs on 1 June 2020, will give an introduction of himself during the presentation. The presentation can be followed as a live webcast (access through the link https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20200514_4) which will also be available on our website. Highlights for the first quarter of 2020: o Despite the temporary halt in clinical trial activities at several hospitals caused by the covid-19 situation, the first site in the INITIUM trial has recently opened for patient inclusion. In total, an opening of 35-40 sites are planned for this trial. Several additional sites are expected to open in Norway and the US during Q2-20. The INITIUM trial is a randomized phase II trial for investigation of UV1 as treatment for first-line patients with metastatic malignant melanoma. o Similarly, the first out of totally six planned sites in the NIPU trial has also opened for patient inclusion. The NIPU trial is a randomized, multi-center phase II trial where UV1 is investigated as second-line treatment in mesothelioma. o In the US based phase I trial in malignant melanoma, in which UV1 is given in combination with a PD-1 checkpoint inhibitor, 8 of the planned 10 patients in cohort 2 (dose finding GM-CSF) have been included as per the reporting date of the Q1-20 report. Four of these patients have been included in the period of covid-19 related lockdown in the US. No unexpected safety issues have been observed to date. o Total operating expenses amounted to MNOK 31.3 in Q1-20. Negative cash flow from operations was MNOK 32.4 in Q1-20. Total cash and cash equivalents was reduced by MNOK 31.5 during Q1-20, amounting to MNOK 367.7 as per 31 March 2020. The report and presentation are also available on the company website. For further information, please see www.ultimovacs.com or contact: Øyvind Kongstun Arnesen, CEO oeyvind.arnesen@ultimovacs.com, +47 469 33810 Hans Vassgård Eid, CFO hans.eid@ultimovacs.com, +47 482 48632